1. Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?

   • Kristen D. Whitaker
   • Deepa Sheth
   • Olufunmilayo I. Olopade

   Review 03 July 2020 Pages: 243 - 250

2. Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound

   • Aubriana M. McEvoy
   • Steven Poplack
   • William E. Gillanders

   Review 10 July 2020 Pages: 251 - 262

   

3. Spatial location of local recurrences after mastectomy: a systematic review

   • Orit Kaidar-Person
   • Philip Poortmans
   • Liesbeth J. Boersma

   Review 13 July 2020 Pages: 263 - 273

   

4. TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of β-catenin

   • Huayan Ren
   • Xiaoyi Mi
   • Huixiang Li

   Review 15 July 2020 Pages: 275 - 289

   

5. Patient preferences for locoregional therapy in early-stage breast cancer

   • Christina A. Minami
   • Tari A. King
   • Elizabeth A. Mittendorf

   Review 20 July 2020 Pages: 291 - 309

6. Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer

   • Albina Stocker
   • Andreas Trojan
   • Zsuzsanna Varga

   Preclinical study 07 July 2020 Pages: 311 - 319

   

7. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy

   • Kai Li
   • Ning Liao
   • Ning Liao

   Preclinical study Open access 07 July 2020 Pages: 321 - 332

   

8. CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ

   • Marina A. Guvakova
   • Indira Prabakaran
   • Paul J. Zhang

   Preclinical study 18 July 2020 Pages: 333 - 346

   

9. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer

   • C. Criscitiello
   • A. Vingiani
   • G. Curigliano

   Clinical trial 03 July 2020 Pages: 347 - 354

   

10. Clinical decision trees support systematic evaluation of multidisciplinary team recommendations

    • Mathijs P. Hendriks
    • Xander A. A. M. Verbeek
    • Agnes Jager

    Clinical trial Open access 06 July 2020 Pages: 355 - 363

    

11. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients

    • Adrienne E. Borrie
    • Finnley A. Rose
    • Richard B. Kim

    Clinical trial 06 July 2020 Pages: 365 - 372

    

12. External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery

    • Ji-Jung Jung
    • Eunyoung Kang
    • Hee-Chul Shin

    Clinical trial 09 July 2020 Pages: 373 - 380

    

13. Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center

    • Emily C. Wong
    • Celia P. Kaplan
    • Michelle Melisko

    Clinical trial 09 July 2020 Pages: 381 - 389

    

14. Patient-reported acute fatigue in elderly breast cancer patients treated with and without regional nodal radiation

    • Shagun Misra
    • Grace Lee
    • Joelle Helou

    Clinical trial 10 July 2020 Pages: 391 - 401

    

15. The shape of breast cancer

    • Brook K. Byrd
    • Venkataramanan Krishnaswamy
    • Richard J. Barth Jr

    Clinical trial 12 July 2020 Pages: 403 - 410

    

16. Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer

    • Bahar Moftakhar
    • Manidhar Lekkala
    • Ajay Dhakal

    Clinical trial 15 July 2020 Pages: 411 - 418

    

17. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

    • Richard S. Finn
    • Katalin Boer
    • Johannes Ettl

    Clinical trial Open access 18 July 2020 Pages: 419 - 428

    

18. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database

    • Zhong-Li Du
    • Yang Wang
    • Bai-Lin Zhang

    Epidemiology 17 July 2020 Pages: 429 - 438

    

19. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study

    • Milena Sant
    • Elisabetta Meneghini
    • the European High Resolution Working Group on breast cancer

    Epidemiology 10 July 2020 Pages: 439 - 450

    

20. “Are changes in breast density during the menstrual cycle relevant? To what?”

    • Jean L. Browne
    • Natalie Korsun
    • M. Angela Pascual

    Epidemiology 15 July 2020 Pages: 451 - 458

    

21. Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer

    • Prudvi Arabandi
    • Alexander N. Slade
    • Vanessa Sheppard

    Epidemiology 16 July 2020 Pages: 459 - 466

22. Obesity and related conditions and risk of inflammatory breast cancer: a nested case–control study

    • Catherine Schairer
    • Cecile A. Laurent
    • Lawrence H. Kushi

    Epidemiology 20 July 2020 Pages: 467 - 478

23. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials

    • Kyaw Zin Thein
    • Thura Win Htut
    • Thein Hlaing Oo

    Brief Report 09 July 2020 Pages: 479 - 487

    

24. Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial

    • Arun Kumar Goel
    • Vaishali Zamre
    • Shreebha Hari

    Letter to the Editor 09 July 2020 Pages: 489 - 490

25. Correction to: Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis

    • Blanche P. Alter
    • Ana F. Best

    Correction 08 July 2020 Pages: 491 - 491

26. Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer

    • Ahrong Ham
    • Min Hwan Kim
    • Joohyuk Sohn

    Correction 14 July 2020 Pages: 493 - 493